17th week of 2015 patent applcation highlights part 50 |
Patent application number | Title | Published |
20150111896 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS - Methods for reducing or preventing the effects of cytotoxic compounds in healthy cells are provided. The methods relate to the use of selective cyclin-dependent kinase (CDK) 4/6 inhibitors to induce transient quiescence in CDK4/6 dependent cells, such as hematopoietic stem cells and/or hematopoietic progenitor cells. Also described is a method of selecting compounds for reducing or preventing the effects of cytotoxic agents compounds in healthy cells. | 2015-04-23 |
20150111897 | TYROSINASE INHIBITORS - The compositions and methods of described herein comprise novel ingredients effective to reduce unwanted pigmentation, such as skin discoloration, freckles, age spots, liver spots, sun damage, tans, pigmented acne marks, scars, pigmented birthmarks, hyperpigmentation, post-inflammatory hyperpigmentation, post-injury hyperpigmentation, melasma, cholasma, after-burn scar, nail stain, yellowing of skin, dark circles under eyes, and the like. The composition may include additional ingredients accordingly for a colored cosmetic, moisturizer, cleanser, toner, and the like. | 2015-04-23 |
20150111899 | PIRFENIDONE THERAPY AND INDUCERS OF CYTOCHROME P450 - The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking. | 2015-04-23 |
20150111900 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS - The present invention relates to compounds described herein Formula (I) and pharmaceutical acceptable salts thereof, which modulate the activity of calcium release-activated calcium (CRAC) channel. The invention also describes the compounds of Formula (I) and pharmaceutical compositions containing such compounds thereof for treating, managing, and/or lessening the severity of diseases, disorders, syndromes or conditions associated with the modulation of calcium release-activated calcium (CRAC) channel. | 2015-04-23 |
20150111901 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES - A pyridone derivative compound and a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof, and a preventive or therapeutic pharmaceutical composition for cognitive disorders that includes the pyridone derivative compound or a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof. | 2015-04-23 |
20150111902 | Methods for Altering MRNA Splicing and Treating Familial Dysautonomia by Administering Kinetin, Benzyladenine, and Tocotrienols - This invention relates to methods for altering the splicing of mRNA in cells. In particular, this invention also relates to methods for increasing the ratio of wild type to misspliced forms of mRNA and corresponding encoded proteins in cells possessing a mutant gene encoding either the i) misspliced mRNA corresponding to the mutant protein or ii) a component in the splicing machinery responsible for processing the misspliced mRNA. In addition, this invention relates to treating individuals having a disorder associated with a misspliced mRNA, such as Familial Dysautonomia or Neurofibromatosis 1, by administering to such an individual a cytokinin such as kinetin. | 2015-04-23 |
20150111903 | PHARMACEUTICAL FORMULATIONS COMPRISING NEUROTROPHIN MIMETICS - Methods and compounds for treating neurodegenerative and other disorders. Included is the administering to a subject in need thereof an effective amount of a compound having binding specificity for a p75 | 2015-04-23 |
20150111904 | PHARMACEUTICAL COMBINATION OF MEK INHIBITOR AND B-RAF INHIBITORS - A novel combination comprising the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl;-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or solvate thereof, with a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or B-Raf is beneficial, eg. melanoma. | 2015-04-23 |
20150111905 | PHARMACEUTICAL COMPOSITIONS OF PEMETREXED - A pharmaceutical composition of Pemetrexed represented by formula (I), which is a liquid ready to use solution formulation or a lyophilized pharmaceutical composition for parenteral administration comprising a pharmaceutically acceptable organic amine, an inert gas and optionally containing at least one or more pharmaceutically acceptable excipients. Also provided are processes for preparation of the ready to use solution formulation or lyophilized pharmaceutical composition of the present invention. | 2015-04-23 |
20150111906 | Synthetic Rigidin Analogues as Anticancer Agents, Salts, Solvates and Prodrugs Thereof, and Method of Producing Same - A compound having the Formula as follows: | 2015-04-23 |
20150111907 | EGFR AND PTEN GENE ALTERATIONS PREDICTS SURVIVAL IN PATIENTS WITH BRAIN TUMOR - The invention relates to methods of predicting the clinical outcome of brain cancer patients based on the LOH levels of the PTEN gene and on the expression levels or the polysomy/amplification levels of EGFR gene in a sample from said patients. | 2015-04-23 |
20150111908 | METHODS OF DIAGNOSING, PREVENTING, AND TREATING BONE MASS DISEASES - The present invention provides methods and therapeutic agents for lowering or increasing serum serotonin levels in a patient in order to increase or decrease bone mass, respectively. In preferred embodiments, the patient is known to have, or to be at risk for, a low bone mass disease such as osteoporosis and the agents are TPH1 inhibitors or serotonin receptor antagonists. | 2015-04-23 |
20150111909 | DOSAGE FORM COMPRISING NON-CRYSTALLINE LOPINAVIR AND CRYSTALLINE RITONAVIR - The present invention relates to an oral dosage form comprising non-crystalline lopinavir and crystalline ritonavir. The invention further relates to methods of preparing said oral dosage forms containing the above pharmaceutical active agents. | 2015-04-23 |
20150111910 | TRIAZOLES AS KV3 INHIBITORS - Compounds of formula (I) are of use in the modulation of Kv3.1, Kv.3.2 and Kv3.3 channels and have utility in the treatment or prevention of related disorders. | 2015-04-23 |
20150111911 | TREATING BAX(DELTA)2-POSITIVE CANCER WITH CHEMOTHERAPIES TARGETING CASPASE 8 - Discovery of a new Bax isoform, BaxΔ2, in cancer cell lines and primary tumors is described. The BaxΔ2 isoform resulted from combination of Bax microsatellite mutation and alternative splicing Bax exon 2. It is also discovered that BaxΔ2 renders cancer cells sensitive to certain chemotherapeutic drugs that target caspase 8. Also provided are methods for treating colorectal cancer by administering to a colorectal cancer patient a chemotherapeutic agent that is capable of activating caspase 8, wherein the patient contains a cancer cell that expresses a BaxΔ2 protein (SEQ ID NO. 2). | 2015-04-23 |
20150111912 | INHIBITORS OF BRUTON'S TYROSINE KINASE - Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase. | 2015-04-23 |
20150111913 | METHOD AND APPARATUS FOR DELIVERY OF A MEASURED DOSAGE OF A NON-AEROSOL, NON-SPRAY FOAM COMPOSITION OF MINOXIDIL - A non-pressurized container that contains one or more of: a foamable composition of minoxidil, or a pharmaceutically acceptable salt thereof, and a dihydrotestosterone blocker in a formulation with a precise density and viscosity to yield a foam with a temperature sensitivity and shear strength designed for inverted application and immediate targeted release at body temperature under a minimal hand applied pressure to the scalp. | 2015-04-23 |
20150111914 | SPIROLACTAM CGRP RECEPTOR ANTAGONISTS - The present invention is directed to spirolactam analogues which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved. | 2015-04-23 |
20150111915 | BENZODIOXOLE OR BENZODIOXEPINE HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS - Compounds of the general formula I | 2015-04-23 |
20150111918 | IMMUNE SYSTEM NEUROMODULATION AND ASSOCIATED SYSTEMS AND METHODS - Methods for treating a patient using therapeutic immune system neuromodulation and associated devices, systems, and methods are disclosed herein. One aspect of the present technology is directed to methods including modulating nerves proximate a vessel or duct of an immune system organ using an intravascularly or intraluminally positioned therapeutic element. One or more measurable physiological parameters corresponding to an immune system disorder, a condition associated with sympathetic activity in an immune system organ, or a condition associated with central sympathetic activity in the patient can thereby be reduced. | 2015-04-23 |
20150111919 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS - Described herein are compositions and methods for treating multiple sclerosis. In particular, described herein are compositions that include one or more dimebolins and/or pharmaceutically acceptable salts thereof and methods for using the compositions for treating multiple sclerosis. | 2015-04-23 |
20150111920 | SELECTIVE EP4 RECEPTOR ANTAGONISTIC SUBSTANCE FOR TREATMENT OF CANCER - This invention provides a medicament for the treatment of cancer, which cause a reduction of cancer. This invention relates to use of a compound which has inhibitory activities against prostaglandin E2 receptor (EP4 receptor) and is represented by the following general formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt for the manufacture of a medicament for the treatment of cancer. The invention relates to a method for treatment of cancer comprising administering the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt to humans or animals. The compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition may be used in combination with one or more second active agents. | 2015-04-23 |
20150111921 | CORTISTATIN ANALOGUES AND SYNTHESES THEROF - The present invention relates to analogs of cortistatin A, J, K, and L, having the general formula: I and salts thereof, wherein R | 2015-04-23 |
20150111922 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES - The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof: (I) in which m, n, W, X, Y, Z, R | 2015-04-23 |
20150111923 | Depot Formulations of a Local Anesthetic and Methods for Preparation Thereof - The invention provides extended release pro-liposomal, non-aqueous, pharmaceutical formulations of a local anesthetic in the form of a clear oily solution and methods for making same. The formulations can be administered by infiltration into an incision, or by injection. | 2015-04-23 |
20150111924 | Controlled Delivery System - The present invention relates to novel anesthetic compositions containing a non-polymeric carrier material and an anesthetic, where the compositions are suitable for providing a sustained local anesthesia without an initial burst and having a duration for about 24 hours or longer. Certain compositions are also provided that include a first anesthetic and a second anesthetic. In such compositions, the second anesthetic is a solvent for the first anesthetic and provides an initial anesthetic effect upon administration to a subject. The non-polymeric carrier may optionally be a high viscosity liquid carrier material such as a suitable sugar ester. The compositions can further include one or more additional ingredients including active and inactive materials. Methods of using the compositions of the invention to produce a sustained anesthetic effect at a site in a subject are also provided. | 2015-04-23 |
20150111925 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS - The present invention relates to compounds described herein Formula (I) and pharmaceutical acceptable salts thereof, which modulate the activity of calcium release-activated calcium (CRAC) channel. The invention also describes the compounds of Formula (I) and pharmaceutical compositions containing such compounds thereof for treating, managing, and/or lessening the severity of diseases, disorders, syndromes or conditions associated with the modulation of calcium release-activated calcium (CRAC) channel. | 2015-04-23 |
20150111926 | SYNERGISTIC PESTICIDAL COMPOSITIONS AND RELATED METHODS - A pesticidal composition comprises a synergistically effective amount of an ecdysone receptor agonist compound and a pesticide selected from N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-((3,3,3-trifluoropropyl)thio)propanamide (I), N-(3-chloro-1-(pyridine-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-((3,3,3-trifluoropropyl)sulfinyl)propanamide (II), or any agriculturally acceptable salt thereof. A method of controlling pests comprises applying the pesticidal composition near a population of pests. A method of protecting a plant from infestation and attack by insects comprises contacting the plant with the synergistic pesticidal composition. | 2015-04-23 |
20150111927 | PHARMACEUTICAL DIAGNOSTIC - The present invention relates to selective cancer treatment regimes based on assaying for the presence or absence of a glutamine or a nucleic acid that encodes glutamine at position 859 of the catalytic p110α subunit of PI3K; methods for producing a transmittable form of information for predicting the responsiveness of patient to (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide), or a pharmaceutically acceptable salt thereof; and a kit thereof. | 2015-04-23 |
20150111928 | Disintegrable Oral Films - A water soluble film that is disintegrable in the oral cavity to deliver an active agent is provided. The disintegrable film includes at least one water soluble polymer and an active agent. Also provided are methods for preparing the disintegrable oral film and for using the disintegrable film to administer an effective dosage of an active agent into the oral cavity for absorption through the oral mucosa. According to certain embodiments, the disintegrable film includes at least one water soluble polymer and a nicotine active. | 2015-04-23 |
20150111929 | PROCESS FOR PREPARING CRYSTALLINE SORAFENIB TOSYLATE - The present invention provides an industrially suitable process for the preparation of substantially pure 4-{4-[({[4-chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide or Sorafenib and its tosylate salt, with a suitable impurity profile and without requirement of any additional purification steps. The present invention also provides Sorafenib base (II) as stable crystalline Form-SSB. | 2015-04-23 |
20150111930 | TOPICAL REGIONAL NEURO-AFFECTIVE THERAPY - A method of treating a disease state or condition in humans via topical brainstem afferent stimulation therapy via the administration of a drug to the back of the neck of a human patient at the hairline in close proximity to and under or on the area of skin above the brain stem to provide regional neuro-affective therapy is disclosed. | 2015-04-23 |
20150111931 | PROCESS FOR THE PREPARATION OF A PDE4 INHIBITOR - The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases. | 2015-04-23 |
20150111932 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DEGENERATIVE DISORDERS - The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing neurological degenerative disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of Parkinson's disease (PD), restless legs syndrome (RLS), cluster headache, depression, fibromyalgia, sexual dysfunction, amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease and depression. | 2015-04-23 |
20150111933 | Deuterated Thiazolidinone Analogues as Agonists for Follicle Stimulating Hormone Receptor - The present invention relates to deuterated thiazolidinone analogues as agonists for follicle stimulating hormone receptor and their use for treating fertility disorders. | 2015-04-23 |
20150111934 | CRYSTALLINE FORMS OF AN ADRENERGIC AGONIST - The present invention relates to the acetate salt of Mirabegron, in particular in two novel crystalline forms, a process for their preparation and the use of said salt and its crystalline forms in the synthesis of Mirabegron with high yields and chemical purity. | 2015-04-23 |
20150111935 | NOVEL 1,3-BENZOXAZOL-2(3H)-ONES AND THEIR USE AS MEDICAMENTS AND COSMETICS - The present invention relates to a novel class of 1,3-benzoxazol-2(3H)-ones and their use as a medicament, preferably as a dermatologic agent, and as a cosmetic. These novel compounds are particularly useful in treating and/or preventing inflammation, irritation, itching, pruritus, pain, oedema and/or pro-allergic or allergic conditions in a patient. Usually they are topically applied to the skin or mucosa in the form of a pharmaceutical or cosmetic composition comprising the compound and a pharmaceutically and/or cosmetically acceptable carrier. | 2015-04-23 |
20150111936 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS - This invention relates to methods for controlling parasitic infestations of animals and their environments, and, more particularly, to methods using isoxazolines to control parasites in or on animals or in their environments, as well as treat parasitoses of animals. The isoxazolines include 4-(isoxazolinyl)-benzamides (specifically, substituted 4-(5-(halomethyl)-5-phenyl-isoxazolin-3-yl)-benzamides) and 4-(isoxazolinyl)-benzothioamides (specifically, substituted 4-(5-(halomethyl)-5-phenyl-isoxazolin-3-yl)-benzothioamides). This invention also relates to compositions comprising the isoxazolines for use in such methods, the use of the isoxazolines to make medicaments for use in such methods, and kits comprising the isoxazolines for carrying out such methods. This invention further relates to the use of the isoxazolines as medicaments, particularly medicaments that can be used in the above-referenced methods. | 2015-04-23 |
20150111937 | Compositions and Methods for Treating Intestinal Hyperpermeability - The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (IBD), graft versus host disease (GVHD), HIV/AIDS, multiple organ dysfunction syndrome, irritable bowel syndrome (IBS), celiac disease, eczema, psoriasis, acute pancreatitis, Parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor. | 2015-04-23 |
20150111938 | PROCESSES FOR THE PREPARATION OF PESTICIDAL COMPOUNDS - The present application provides processes for making pesticidal compounds and compounds useful both as pesticides and in the making of pesticidal compounds. | 2015-04-23 |
20150111939 | Pharmaceutical Dosage Forms Comprising 6'-Fluoro-(N-Methyl- or N,N-Dimethyl-)-4-Phenyl-4',9'-Dihydro-3'H-Spiro[Cyclohexane-1,1'-Pyrano[3- ,4,b]Indol]-4-Amine - A pharmaceutical dosage form for administration twice daily, once daily or less frequently, which contains 6′-fluoro-(N-methyl- or N,N-dimethyl)-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine or a physiologically acceptable salt thereof. | 2015-04-23 |
20150111940 | ASCORBIC ACID SALT OF SUNITINIB - The present invention relates to an ascorbic acid salt of sunitinib and a process for its preparation. The present invention further provides a crystalline Form I of an L-ascorbic acid salt of sunitinib. | 2015-04-23 |
20150111941 | USE OF MELATONIN - The present invention relates to melatonin or a pharmaceutically acceptable salt thereof for use as a medicament, the use of melatonin or a pharmaceutically acceptable salt thereof for the preparation of medicament, the use of melatonin as a food supplement and a pharmaceutical unit dosage form. | 2015-04-23 |
20150111942 | IPA AS A THERAPEUTIC AGENT, AS A PROTECTIVE AGENT, AND AS A BIOMARKER OF DISEASE RISK - Indole-3-propionic acid as a marker and for treatment for Huntington Disease. | 2015-04-23 |
20150111943 | HYDROXYMETHYLFURFURAL DERIVATIVE - The hydroxymethylfurfural derivative is represented by the general formula (A) (wherein, R is selected from the group consisting of the following formula (I), (II) HOOCCH | 2015-04-23 |
20150111944 | INSECTICIDAL COMPOUNDS - The invention relates to compounds of formula (I): | 2015-04-23 |
20150111945 | COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS GENE EXPRESSION - The present invention provides compositions comprising therapeutic nucleic acids (e.g., interfering RNA such as siRNA) that target Ebola virus (EBOV) gene expression and methods of using such compositions to silence EBOV gene expression. More particularly, the invention provides unmodified and chemically modified interfering RNA which silence EBOV gene expression and methods of use thereof, e.g., for preventing or treating EBOV infections caused by one or more EBOV species such as Zaire EBOV. The invention also provides serum-stable nucleic acid-lipid particles comprising one or more interfering RNA molecules, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. Methods of silencing EBOV gene expression by administering one or more interfering RNA molecules to a mammalian subject are also provided. | 2015-04-23 |
20150111946 | METHODS FOR DELIVERY TO THE CENTRAL NERVOUS SYSTEM OF NUCLEIC ACID NANOPARTICLES TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS - Disclosed herein are methods and compositions for the treatment of diseases of the CNS with nucleic acid nanoparticles. Compositions are also disclosed herein that utilize nucleic acid nanoparticles to treat conditions such as Parkinson's Disease. Furthermore, methods of intranasally administering the compacted nucleic acid nanoparticles for therapeutic purposes in the brain are disclosed. | 2015-04-23 |
20150111947 | COMPOSITIONS AND METHODS FOR DECREASING LEUKOCYTE EXTRAVASATION AND VESSEL FLUID LEAKAGE - Provided herein are methods of decreasing leukocyte extravasation from a lymph or blood vessel into a tissue in a mammal, methods of decreasing fluid leakage from a lymph or blood vessel in a mammal in need thereof, methods of decreasing formation of atherosclerotic plaques in a mammal in need thereof, and methods of treating atherosclerosis in a mammal that include administering to the mammal an oligonucleotide that decreases Mitogen-activated protein kinase kinase kinase kinase 4 (Map4k4) mRNA expression in an endothelial cell. Also provided are methods of identifying a candidate agent useful for decreasing leukocyte extravasation or decreasing fluid leakage from a lymph or blood vessel in a mammal, and compositions containing an oligonucleotide that decreases Map4k4 mRNA expression in an endothelial cell and additional therapeutic agents. | 2015-04-23 |
20150111948 | RNA-INTERFERENCE-INDUCING NUCLEIC ACID MOLECULE ABLE TO PENETRATE INTO CELLS, AND USE THEREFOR - The present invention relates to a novel, RNAi-inducing nucleic acid molecule having cell penetrating ability and the use thereof, and more particularly, to a novel, RNAi-inducing double-stranded nucleic acid molecule, which has a replacement of the phosphate backbone of at least one nucleotide with phosphorothioate or phosphorodithioate, and has a lipophilic compound conjugated thereto, and thus has high target gene-silencing efficiency while having the ability to penetrate cells without needing a separate intracellular delivery vehicle, and to a method of silencing a target gene using the nucleic acid molecule. The nucleic acid structure according to the present invention has both cholesterol modification and phosphorothioate modification introduced therein, and thus has high gene silencing efficiency while having the ability to penetrate cells without needing a separate intracellular delivery vehicle. Thus, it can be delivered into an actual target area in an amount sufficient for induction of RNAi, and thus can overcome the in vivo delivery problem occurring in the prior art. Therefore, the nucleic acid molecule according to the invention can effectively substitute for conventional siRNA molecules to treat cancer or viral infections. | 2015-04-23 |
20150111949 | TREATMENT OF CANCERS WITH MICRO-RNA INHIBITORS - The invention relates to the treatment and prevention of cancers, including blood-based cancers and breast cancers, by administering agents that inhibit the activity of microRNAs, including miR-22. Inhibitors can include oligonucleotides that are at least partially complementary to these miRNAs. In some embodiments, these inhibitors are chemically modified oligonucleotides, including locked nucleic acids (LNAs). | 2015-04-23 |
20150111950 | INHIBITION OF DNA2 IN FANCONI ANEMIA - Inhibition of DNA2 in Fanconi anemia (FA) cells remedies the over-resection of DNA, thereby stabilizing the FA cells. Inhibition of DNA2 in FA cells allows for safe treatment of cancers in FA patients, a decrease in the lethality of FA cells, a decrease in bone marrow failure of FA patients, and a means for decreasing the incidence of cancer for FA patients. | 2015-04-23 |
20150111951 | METHODS FOR THE TREATMENT OF LEBER CONGENITAL AMAUROSIS - The present invention relates to a method for treating a Leber congenital amaurosis in a patient harbouring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.2291+1655 A>G CEP290 mRNA | 2015-04-23 |
20150111952 | METHOD FOR TREATING GLIOMA USING TARBP2 EXPRESSION INHIBITOR - A method of preventing or treating glioma by inhibiting expression of Tarbp2, which is a novel transcription factor inducing Notch signal activation, and a pharmaceutical composition for treating glioma using shRNA or siRNA as a Tarbp2 expression inhibitor, as well as a method of treating glioma using the same and use thereof, are provided. | 2015-04-23 |
20150111953 | Modulator Compounds of Drug Resistance in Epithelial Tumor Cells - The described invention provides a method of treating a patient with an epithelial cancer comprising administering a composition comprising a therapeutic amount of an inhibitor of a BTK protein and one or more chemotherapeutic agent(s) selected from the group consisting of an antimetabolite, a platinum coordination compound, an alkylating agent and a combination thereof, wherein the composition is effective to reduce one or more of tumor cell growth, tumor cell clonogenicity, tumor cell proliferation, tumor cell viability and tumor volume and the therapeutic amount of the inhibitor of a BTK protein and the one or more chemotherapeutic agent(s) exerts a synergistic effect. The described invention also provides methods of treating a chemotherapy drug-resistant cancer and sensitizing a cancer patient to chemotherapy. | 2015-04-23 |
20150111954 | LIN28/LET-7 CRYSTAL STRUCTURES, PURIFICATION PROTOCOLS, AND MOLECULAR PROBES SUITABLE FOR SCREENING ASSAYS AND THERAPEUTICS - The invention provides compositions and methods for regulating microRNA (miRNA) biogenesis. The invention also relates to compositions and methods for treating or preventing cancer in a subject in need thereof. | 2015-04-23 |
20150111955 | AAV VECTOR COMPOSITIONS AND METHODS FOR GENE TRANSFER TO CELLS, ORGANS AND TISSUES - The invention relates to adeno-associated virus (AAV) serotype AAV-Rh74 and related AAV vectors, and AAV-Rh74 and related AAV vector mediated gene transfer methods and uses. In particular, AAV-Rh74 targets polynucleotides to cells, tissues or organs for expression (transcription) of genes encoding therapeutic proteins and peptides, and polynucleotides that function as or are transcribed into inhibitory nucleic acid sequences. | 2015-04-23 |
20150111956 | FORMULATIONS FOR THE DELIVERY OF ACTIVE INGREDIENTS - This invention relates generally to in vivo delivery of active ingredient formulations. More particularly, this invention relates to formulations of active ingredients that further comprise an agent, methods of making such formulations, and methods of using the same. | 2015-04-23 |
20150111957 | Endothelial Cell-Specific Polynucleotides and Use Thereof - An isolated polynucleotide is disclosed comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence of HIF-1alpha, the polypeptide being stably expressed and constitutively active. Isolated polypeptides encoded by same are also disclosed and uses thereof. | 2015-04-23 |
20150111958 | PHOSPHORODIAMIDATE BACKBONE LINKAGE FOR OLIGONUCLEOTIDES - This invention relates to antisense oligonucleotides comprising at least one N3′→P5′ phosphorodiamidate linkage (NPN) in the backbone as well as methods for using the same. The antisense oligonucleotides can effectively prevent or decrease protein expression. | 2015-04-23 |
20150111959 | Choline Esters - Compounds, formulations, and methods are provided containing the choline ester of a reducing agent, especially lipoic acid or derivatives thereof. The compounds may be administered via a topical ocular route to treat or prevent oxidative damage. | 2015-04-23 |
20150111960 | NOVEL FORMULATIONS OF PHARMACOLOGICAL AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF - In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts as a stabilizing agent). In particular, protein and pharmacologically active agent in a biocompatible dispersing medium are subjected to high shear, in the absence of any conventional surfactants, and also in the absence of any polymeric core material for the particles. The procedure yields particles with a diameter of less than about 1 micron. The use of specific composition and preparation conditions (e.g., addition of a polar solvent to the organic phase), and careful selection of the proper organic phase and phase fraction, enables the reproducible production of unusually small nanoparticles of less than 200 nm diameter, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a redispersible dry powder comprising nanoparticles of water-insoluble drug coated with a protein, and free protein to which molecules of the pharmacological agent are bound. This results in a unique delivery system, in which part of the pharmacologically active agent is readily bioavailable (in the form of molecules bound to the protein), and part of the agent is present within particles without any polymeric matrix therein. | 2015-04-23 |
20150111961 | MEMBRANE FUSION INHIBITOR - The present invention provides a pharmaceutical composition that has excellent safety and targets a different step in the virus propagation cycle than conventional pharmaceutical compositions, applicable as an antiviral agent. A pharmaceutical composition containing an epigallocatechin gallate derivative represented by the following chemical formula (1), an isomer thereof, or a salt thereof is prepared. This can be used as a membrane fusion inhibitor that inhibits viral membrane fusion. In the following formula, R | 2015-04-23 |
20150111962 | COMPOUNDS AND METHODS FOR TREATING AIDS AND HIV INFECTIONS - Macrocycle containing carbamate compounds that inhibit HIV proteolytic enzymes and processes for preparing them are described. Compositions and methods for treating a patient infected with HIV are described. | 2015-04-23 |
20150111963 | FUMIGILLOL TYPE COMPOUNDS AND METHODS OF MAKING AND USING SAME - The disclosure provides a fumagillol type compound and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of using, e.g. in the treatment of obesity are provided. | 2015-04-23 |
20150111964 | POLYMORPHIC SALT OF A METAP-2 INHIBITOR AND METHODS OF MAKING AND USING SAME - The disclosure is in part directed to crystalline forms of an oxalate salt of 6-O-(4-dimethylaminoethoxy)cinnamoyl fumagillol. | 2015-04-23 |
20150111965 | ORALLY BIOAVAILABLE PENTAMIDINE PRODRUGS FOR THE TREATMENT OF DISEASES - The present invention relates to prodrug derivatives of pentamidine, their use in the treatment and/or prophylaxis of diseases such as tumor diseases, as well as leishmaniasis, trypanosomiasis, pneumocystis carinii pneumonia (PcP), and malaria. | 2015-04-23 |
20150111966 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FIBROMYALGIA PAIN - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of fibromyalgia pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, post herpetic neuralgia, diabetic neuropathy, bipolar depression, stress, cancer pain, and lower back pain. | 2015-04-23 |
20150111967 | METHOD FOR MAKING A PEROXYCARBOXYLIC ACID - The present invention relates to apparatus and methods for making a peroxycarboxylic acid. The apparatus includes a reaction catalyst and a guard column for pretreating one or more reagents, which can increase the life, activity, and/or safety of the reaction catalyst. The peroxycarboxylic acid compositions made by the method and apparatus can include one or more peroxycarboxylic acids. | 2015-04-23 |
20150111968 | METHODS AND KITS FOR ENHANCING THE ABILITY TO LEARN IN A PUPPY OR KITTEN - Disclosed herein are processes for enhancing ability to learn in a puppy or kitten comprising orally administering to the puppy or kitten a composition comprising an essential fatty acid component comprising a therapeutically effective amount of docosahexaenoic acid. | 2015-04-23 |
20150111969 | J-SERIES PROSTAGLANDIN-ETHANOLAMIDES AS NOVEL THERAPEUTICS - Provided is a compound of formula (I): | 2015-04-23 |
20150111970 | GENETIC MARKERS AND DIAGNOSTIC METHODS FOR RESISTANCE OF BREAST CANCER TO HORMONAL THERAPIES - This application provides a method to identify genetic markers associated with increased sensitivity or resistance to hormonal therapies using an outlier analysis. More specifically, this application discloses that amplifications on chromosomes 8 and 17 are associated with increased proliferation and poor outcome in ER-positive breast cancer, and amplicons 17q21.33-q25.1, 8p11.2 and 8q24.3 may be responsible for higher proliferation and poor outcome in the setting of antiestrogen, in particular Tamoxifen, treatment clinically observed in a subset of ER-positive, HER2-negative breast cancers. The invention also provides use of the identified genetic markers in the development of targeted treatments for antiestrogen-resistant ER-positive breast cancers as well as in improving current methods of drug response prediction. | 2015-04-23 |
20150111971 | TOPICAL PHARMACEUTICAL COMPOSITIONS - The present invention relates to a topical pharmaceutical composition comprising, based on the total weight of the composition:
| 2015-04-23 |
20150111972 | ALCOHOL-CONTAINING COMPOSITIONS USEFUL AS SOLID FUELS AND PROCESSES FOR THEIR MANUFACTURE - There is provided a composition comprising: (a) from about 60 to about 98% by weight of one or more alcohols; (b) from about 0.5 to about 20% by weight of one or more alkyl cellulose derivatives, wherein each alkyl is optionally substituted with one or more OH, O-alkyl, O-hydroxyalkyl and/or O-alkoxyalkyl; (c) from about 1 to about 25% by weight of one or more carboxylic acid salts; and (d) from 0 to about 30% by weight of water. There is also provided uses, processes for manufacture, methods and products relating to the same. | 2015-04-23 |
20150111973 | METHODS OF MODULATING STEROID HORMONE ACTIVITY - The present invention relates to methods of treating steroid hormone related disorders by modulating steroid hormone activity. | 2015-04-23 |
20150111974 | Method and Device for Generating Hydrogen Plasma Field - A method for generating a hydrogen plasma field include a step for preparing ionized hydrogen water in which hydrogenated hydrogen with ion binding properties or ortho hydrogen molecules have been dissolved. The method also includes a step for irradiating the resulting solution with vacuum ultraviolet light. The vacuum ultraviolet light preferably includes waves with a wavelength of 193 nm. Applying this method for generating a hydrogen plasma field to an oil emulsification step enables an emulsified oil to be better refined and converted to atomized particles through exposure to sunlight. | 2015-04-23 |
20150111975 | CATALYST FOR METHANOL PRODUCTION, METHOD OF PRODUCING THE SAME AND PROCESS OF METHANOL PRODUCTION - [Problem] The present invention is to provide a catalyst used for a process for preparing methanol from carbon dioxide and hydrogen and the catalyst has high activity and excellent stability with the passage of time in reactivity. | 2015-04-23 |
20150111976 | MULTIFUNCTIONAL POROUS ARAMIDS (AEROGELS) AND FABRICATION THEREOF - The present disclosure provides a series of new and improved porous polyamide aerogels derived from multifunctional aromatics that combine the high mechanical strength of aramids with the pore structure of aerogels. The polyamide aerogels have a hyperbranched structure, relatively low density, high porosity and may be derived from functionalized monomers having more aromatic groups than functional groups. The present disclosure also provides a new method for producing the porous polyamide aerogels by polymerizing an aromatic multifunctional carboxylic acid or a ferrocene multifunctional carboxylic acid with a polyfunctional aromatic isocyanate at moderate reaction conditions followed by drying with liquid CO | 2015-04-23 |
20150111977 | Low Dust, Light Weight Filler Composition - A filler composition for use in a casting formulation, where the filler composition includes a mineral filler, hollow plastic microspheres, and a food grade and non-flammable liquid, and where when the filler composition is mixed with a casting resin an OSHA 8-hour Permissible Exposure Limit set for Particulates Not Otherwise Regulated is not exceeded. | 2015-04-23 |
20150111978 | METHOD OF FORMING DUAL CURABLE POLYMER COMPOSITIONS - The present disclosure provides a method of preparing a dual curable polymer, the method comprising the steps of: (a) reacting a peripheral reactive group of a dendritic polymer with a cross-linker compound having two or more moisture curable functional groups to form a functionalized dendritic polymer terminated with the moisture curable functional groups; and (b) reacting said functionalized dendritic polymer with an acrylic compound to form a substituted dendritic polymer having a mixture of acrylate functional groups and at least one peripheral moisture curable functional group. | 2015-04-23 |
20150111979 | METHOD FOR CURING STRUCTURES USING A DUAL PHOTOINITIATOR SYSTEM AND A STRUCTURE MADE USING THE SAME - A monomeric formulation for fabrication of microlattice structures, the monomeric formulation including a plurality of monomers, a first photoinitiator configured to substantially activate above a wavelength of light, and a second photoinitiator configured not to substantially activate above the wavelength of light and to substantially activate below the wavelength of light. | 2015-04-23 |
20150111980 | POLYISOCYANATE ADDUCTS AS ADDITIVES FOR RADIATION-CURABLE COATING MATERIAL COMPOSITIONS - The invention relates to polyisocyanate adducts obtainable by reacting at least one polysiloxane of the structure (I), at least one polyisocyanate having at least three NCO groups, at least one (meth)acrylate of the structure (II), where U is one of the following groups: (III), and optionally a compound reactive with isocyanates. The indices m, n, x and y assume values of 0 to 100. In addition, t=2 to 30, s=1 to 400 and i=1 to 5. The radicals identified by the letter R are suitable organic groups. A | 2015-04-23 |
20150111981 | Method of preparing UV-curable Inkjet Pigment Ink for Textile Printing - The present invention provides a method of preparing UV-curable inkjet pigment ink for textile printing, in which mini-emulsion techniques are used to encapsulate monomer, photo initiator, thermal initiator and pigment in mini-emulsion particles to make a UV-curable pigment paste, and the UV-curable pigment paste is mixed with water-soluble co-solvent, surfactant and water to make a UV-curable pigment ink. The preparation process is simple and easy. The UV-curable inkjet pigment ink of the invention exhibits good fluency during printing, bright color and strong color fastness in printed products. | 2015-04-23 |
20150111982 | COMB-COIL SPRAMOLECULAR CROSSLINKED POLYMER - The present invention relates to a facile process for the preparation of non-covalently cross-linked self-assembled perylene bisimide nano structures using hydrogen bonding interactions with poly-4-vinyl pyridine or oligophenylene vinylene (OPV) as structural motif. | 2015-04-23 |
20150111983 | MATERIAL FOR CONTACT LENSES, METHOD FOR MANUFACTURING CONTACT LENSES AND CONTACT LENSES OBTAINED THEREBY - The method for manufacturing contact lenses includes the following steps. First, a first siloxane macromer, a second siloxane macromer, at least one hydrophilic monomer, an initiator and a solvent are mixed to form a mixture. Then the mixture is injected into a mold of contact lens and conducted by a thermal treatment or a UV irradiating treatment to form contact lenses. The number average molecular weight of the first siloxane macromer represented by the following formula (I), is 1,000 to 10,000 and the first siloxane macromer has a cross-linking function. | 2015-04-23 |
20150111984 | INSECT-REPELLENT, WATER-BASED, FIREPROOF VINYL-ACRYLIC THERMAL PAINT COMPRISING PHASE-CHANGE MATERIALS - This remarkable invention provides: a vinyl-acrylic water base paint that contains encapsulated phase change materials of oleoresin from capsaicin or capsicum, derived directly from the placenta of the chili pepper. The paint also has fire-retardant properties, in one of its modes. The paint is also used to maintain the temperature of a closed enclosure, in a zone of temperature that depends on the components of phase change materials and where they can work in a range of temperatures suitable for zones of comfort and cooling areas, saving costs because of less use of air conditioning and heating equipment systems. | 2015-04-23 |
20150111985 | RUBBER COMPOSITION AND PNEUMATIC TIRE USING SAME - The present invention provides a rubber composition formed by blending from 1 to 100 parts by mass of carbon black and/or from 5 to 150 parts by mass of an inorganic filler, from 0.5 to 30 parts by mass of a sulfur-containing compounding agent, and from 0.01 to 20 parts by mass of a boron-containing compounding agent into 100 parts by mass of a sulfur-crosslinkable diene rubber, and a pneumatic tire in which the rubber composition is used in at least one type selected from the group consisting of a capped tread, a side wall, a belt, an inner liner, a carcass, and a bead. | 2015-04-23 |
20150111986 | POLYOLEFIN INTUMESCENT PHOSPHOROUS FLAME RETARDANT SYSTEM - A flame retardant polypropylene compound is disclosed. The compound comprises a polypropylene and non-halogenated ammonium phosphate flame retardant, along with ethylene vinyl acetate, magnesium hydroxide; fluoroelastomer and other functional additives. The compound can achieve a UL 94 rating of V-0 at a thickness of 1.55 mm or greater. | 2015-04-23 |
20150111987 | SELF-HEALING AGENT FORMULATIONS CONTAINING LIQUID CORROSION INHIBITORS - Disclosed herein are self-healing systems that include corrosion inhibitors and self-healing materials that are capable of repairing themselves without any external intervention when they are damaged. The self-healing materials and corrosion inhibitors may be microencapsulated, and damage to a matrix containing the microcapsules may rupture the microcapsules and cause the self-healing materials and corrosion inhibitors to be released into the site of damage. The self-healing materials then may polymerize and restore the functional capabilities of the matrix, and the corrosion inhibitors may work in concert with the self healing materials to prevent corrosion at the site of damage. | 2015-04-23 |
20150111988 | MOLDED ARTICLE AND METHOD OF PRODUCING THE SAME - The present invention relates to a molded article exhibiting a low linear expansion coefficient and a method of producing the molded article. The molded article is molded from a resin composition containing at least a thermoplastic cyclic olefin resin and silica particles surface-modified with amino functional groups and having a number average particle diameter of primary particles of 10 nm or more and 50 nm or less. The resin composition contains the silica particles in an amount of 34% by mass or more and 85% by mass or less. | 2015-04-23 |
20150111989 | SET OF INK AND PRETREATMENT LIQUID - A set of an ink and a pretreatment liquid includes a white-based ink composition containing a white-based color material and a pretreatment liquid containing a flocculant, in which the white-based color material consists of second particles which have an average particle size from 200 nm to 1 μm and which are formed by aggregating a plurality of first particles having an average particle size of less than 200 nm, in which the flocculant flocculates the second particles, and in which the white-based ink composition is preferably adhered onto a region of a recording medium onto which the pretreatment liquid is imparted so that the white-based color material is 0.1 mg/cm | 2015-04-23 |
20150111990 | COATING COMPOSITION WITH IMPROVED ADHESION TO A SUBSTRATE - A process for providing a coating with improved adhesion to a substrate is provided. The coating composition comprises an epoxy function polymer, a fully alkylated melamine resin and an amidoamine. The process involves forming a mixture of the film forming components and allowing the mixture to mature before adding an acid catalyst. The result is a layer of the coating composition with a high degree of adhesion to the substrate. | 2015-04-23 |
20150111991 | AROMATIC ALDEHYDE, AND EPOXY RESIN CURING AGENT AND EPOXY RESIN COMPOSITION COMPRISING THE AROMATIC ALDEHYDE - There are provided a novel aromatic aldehyde compound capable of providing an epoxy resin coating film and an epoxy resin cured material satisfying all of the excellent surface property (smoothness, gloss), drying property, water resistance, transparency and adhesion, and an epoxy resin curing agent and an epoxy resin composition containing the aromatic aldehyde compound. The aromatic aldehyde has a branched alkyl group having 10 to 14 carbon atoms. | 2015-04-23 |
20150111992 | BARIUM SULFATE COMPOSITE PARTICLE, RESIN COMPOSITION COMPRISING THE SAME, AND PRODUCTION METHOD THEREOF - As barium sulfate which is used as a filler of a resin composition for an electronic equipment, a precipitated barium sulfate which is synthesized from barium sulfide contains a sulfur component as an impurity so that metal parts such as electrodes of electronic parts maybe deteriorated and corroded by a hydrogen sulfide component volatilized from the barium sulfate to reduce the function, the durability, and the reliability of electronic equipment when used for resin compositions such as an ink, a film, and a sheet which are used for an electronic equipment. | 2015-04-23 |
20150111993 | NOVEL COMPOSITE COMPOSITIONS AND NEW AND NOVEL MACHINE AND CONTACT TOOLS - Composite compositions and machine and contact tools, for example, metal boring tools and face mills that are manufactured from them. The tools are provided with composite structure to lighten the tools and yet retain the strength and durability of the tool. The novelty resides in the use of additives to certain composites that make up a portion of the tool, especially tool bars. | 2015-04-23 |
20150111994 | EPOXY-AMINE ADDUCT, RESIN COMPOSITION, SIZING AGENT, CARBON FIBER COATED WITH SIZING AGENT, AND FIBER-REINFORCED COMPOSITE MATERIAL - Provided is an epoxy-amine adduct that offers high reactivity, contributes to better adhesion between a resin and a reinforcing fiber in a fiber-reinforced composite material, and can be easily blended with another component such as a resin. The epoxy-amine adduct has two or more amino groups per molecule and is obtained by a reaction of an epoxy compound (A) having two or more alicyclic epoxy groups per molecule with an amine compound (B) having two or more amino groups per molecule. The epoxy compound (A) is preferably a compound represented by Formula (a): | 2015-04-23 |
20150111995 | CARBOXYL GROUP CONTAINING ACRYLIC RDP AND DRY MIX CEMENT FORMULATIONS CONTAINING THEM - The present invention provides water redispersible polymer powder (RDP) compositions that perform well even when redispersibility is fair comprising carboxyl group containing multi-stage acrylic copolymers having an alkali-soluble resin outer stage and one or more inner stage acrylic (co)polymer having a glass transition temperature (Tg) of from −40 to 50° C., one or more nucleating agent having a boiling point of 150° C. to 500° C., and a water solubility of 3.5% or less, preferably, an alkyl isobutyrate and a branched alkyl isobutyrate, and one or more colloidal stabilizer. Also provided are dry mix cement tile adhesive compositions comprising the water redispersible polymer powder an ordinary Portland cement, an alumina rich cement with an alumina content of from 30 wt. % to 85 wt. %, and calcium sulfate. The invention enables a broad range of the claimed acrylic polymers in useful RDPs. | 2015-04-23 |
20150111996 | THERMOPLASTIC RESIN COMPOSITIONS - A thermoplastic resin composition that may contain plant fine powders that are kicked up when a plant is pulverized. Such plant fine powders have an average particle diameter of 20 μm or less. Standard deviation of particle diameters are 15 μm or less. Content of the plant fine powders is less than 50 wt %. | 2015-04-23 |
20150111997 | Process for Manufacturing a Composition Comprising Cellulose Pulp Fibers and Thermoplastic Fibers - The invention relates to a process for manufacturing a composition comprising cellulose pulp fibers and thermoplastic fibers wherein said process comprises the step of: a) mixing a refined aqueous pulp suspension with a water suspension of thermoplastic fibers. The invention also relates to compositions and composite articles obtainable by said process. | 2015-04-23 |
20150111998 | METHOD FOR PRODUCING RUBBER COMPOSITION AND RUBBER COMPOSITION - A method for producing a rubber composition include a mixing step, a drying step, and a dispersion step. In the mixing step, an aqueous solution that includes at least one of oxycellulose fibers and cellulose nanofibers is mixed with rubber latex to obtain a first mixture. In the drying step, the first mixture is dried to obtain a second mixture. In the dispersion step, the second mixture is tight-milled using an open roll to obtain a rubber composition. The rubber composition does not include an aggregate that includes at least one of the oxycellulose fibers and the cellulose nanofibers, and has a diameter of 0.1 mm or more. | 2015-04-23 |